Arca
Skip to content

Macitentan

ANDA 211000, held by Amneal. Macitentan.

  • First approved: Jun 8, 2026
  • Review: Standard
  • Supplements approved: 0
  • Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first
DateSubmissionStatusDocuments
Jun 8, 2026Original applicationApprovedLetterLetter

Products

1 strengths and forms
ProductActive ingredientMarketing
Macitentan10MG · tablet;oralMacitentanRx

Identifiers

Application
ANDA 211000

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.